-
Cubist Pharmaceuticals LLC. v. Mylan Laboratories Limited et al DC CAFC
- 1:13-cv-01679
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 10/09/2013
- Closed: 02/02/2016
- Latest Docket Entry: 07/19/2016
- PACER
- Docket updated daily
2
Plaintiffs
4
Defendants
1
Accused
Product
4
Patents-in-Suit
847
Days in
Litigation
-
Cubist Pharmaceuticals LLC. v. Mylan Laboratories Limited et al DC CAFC
- 1:13-cv-01679
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 10/09/2013
- Closed: 02/02/2016
- Latest Docket Entry: 07/19/2016
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
91 |
The method of claim 85 wherein the composition is daptomycin that is essentially free of each of impurities 1 to 14 defined by peaks 1-14 shown in <figref idref="DRAWINGS">FIG. 12</figref>.
|
Invalid
Entry 64 |
98 |
The composition of claim 97, wherein the size selection technique is ultrafiltration or size exclusion chromatography.
|
Invalid
Entry 64 |
187 |
The composition of claim 183, wherein the daptomycin composition is at least or about 97% pure.
|
Invalid
Entry 64 |
Claim # | Claim Text | Outcome |
---|---|---|
16 |
The method according to claim 14, wherein the dose is 4 mg/kg administered once every 24 hours.
|
Invalid
Entry 64 |
17 |
The method according to claim 14, wherein the dose is 6 mg/kg administered once every 24 hours.
|
Invalid
Entry 64 |
34 |
The method according to claim 33, wherein the dose is 4 mg/kg.
|
Invalid
Entry 64 |
35 |
The method according to claim 33, wherein the dose is 6 mg/kg.
|
Invalid
Entry 64 |
Claim # | Claim Text | Outcome |
---|---|---|
23 |
The pharmaceutical composition of claim 22, wherein the daptomycin is obtained from the daptomycin aggregate by a method comprising the steps of a) filtering the daptomycin aggregate under conditions in which the daptomycin aggregate is retained on
view more
|
Invalid
Entry 64 |
53 |
The composition of claim 52, wherein a) the composition is a lyophilized powder compatible with a pharmaceutically acceptable carrier for the treatment of an infection by a daily intravenous dose of 1 to 12 mg/kg of the daptomycin in a reconstituted
view more
|
Invalid
Entry 64 |
-
Infringement
Agila Specialties Inc.
- 4 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
500mg/vial daptomycin for injection | US 6,468,967 B1 |
16, 17, 34, 35
|
Infringement
Entry 64
|
500mg/vial daptomycin for injection | US 6,852,689 B2 |
51, 52
|
Infringement
Entry 64
|
500mg/vial daptomycin for injection | US 8,058,238 B2 |
91, 98, 187
|
Infringement
Entry 64
|
500mg/vial daptomycin for injection | US 8,129,342 B2 |
23, 53
|
Infringement
Entry 64
|
Mylan Laboratories Limited
- 4 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
500mg/vial daptomycin for injection | US 6,468,967 B1 |
16, 17, 34, 35
|
Infringement
Entry 64
|
500mg/vial daptomycin for injection | US 6,852,689 B2 |
51, 52
|
Infringement
Entry 64
|
500mg/vial daptomycin for injection | US 8,058,238 B2 |
91, 98, 187
|
Infringement
Entry 64
|
500mg/vial daptomycin for injection | US 8,129,342 B2 |
23, 53
|
Infringement
Entry 64
|